sub:assertion {
  d:DB00398 v:identifier "DB00398" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00398" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00398> ;
    dv:drugbank-id "APRD01304" , "DB00398" , "DB07438" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:92:00.00> ;
    dv:x-atc <http://bio2rdf.org/atc:L01XE05> ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:16673> ;
    dv:x-cas <http://bio2rdf.org/cas:284461-73-0> ;
    dv:x-chebi <http://bio2rdf.org/chebi:50924> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:187440> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D08524> ;
    dv:x-ndc <http://bio2rdf.org/ndc:50419-488-58> ;
    dv:x-pdb <http://bio2rdf.org/pdb:BAX> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA7000> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:216239> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46505329> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Sorafenib> ;
    dct:description """Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received \"Fast Track\" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.
Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway."""@en ;
    dct:identifier "drugbank:DB00398" ;
    dct:title "Sorafenib"@en ;
    a dv:Drug ;
    rdfs:label "Sorafenib [drugbank:DB00398]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00398> , <http://www.drugs.com/cdi/sorafenib.html> , <http://www.rxlist.com/nexavar-drug.htm> .
}